Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST ~.E TOME 1 DE 2
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional vohxmes please contact the Canadian Patent Oi~ice.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
CRYSTALS OF AN AURORA-A TPX2 COMPLEX, TPX2 BINDING SITE OF AURORA-A,
AURORA-A LIGANDS AND THEIR USE
The present invention relates to crystals of phosphorylated Aurora-A kinase
fragment alone
and in complex with a ligand, amino acid residues 1-43 of human TPX2. This
invention also
relates to methods for designing and selecting figands, in particular
allosteric inhibitors of
Aurora-A, that bind to the Aurora-A kinase and their use. Further, the present
invention
relates to certain indene and indole derivatives.
At the beginning of mitosis, eukaryotic cells undergo a dramatic
reorganization. The nuclear
envelope breaks down and microtubules rearrange around chromatin into a
bipolar spindle
structure that carries out the duty of separating sister chromatids. Chromatin
signals to the
spindle assembly machinery through Ran, a small Ras-like GTPase that is
concentrated in
its GTP-bound form around chromatin. Ran function in spindle assembly is
connected to its
role in nucleocytoplasmic transport. RanGTP releases crucial spindle assembly
factors such
as TPX2 and NuMA from the transport factors that mediate their import into the
nucleus at
interphase. After nuclear envelope breakdown, the presence of free TPX2 in the
vicinity of
chromatin is thought to nucleate microtubules that are subsequently organised
into a spindle
by microtubule motors. Additionally, TPX2 localises an essential mitotic
kinase, Aurora-A, to
spindle microtubules ( Kufer, T. A., Sillje, H. H., Korner, R., Gruss, O. J.,
Meraldi, P., and
Nigg, E. A. (2002). Human TPX2 is required for targeting Aurora-A kinase to
the spindle. J.
Cell Biol. 758, 617-623).
Aurora kinases constitute a family of serine-threonine protein kinases whose
localization and
activities are precisely choreographed as a cell progresses through mitosis.
Aurora-A is a
cell-cycle regulated serine-threonine kinase involved in chromosome
segregation and
cytokinesis (Bischoff, J.R. and Plowman, G.D. (1999). The Aurora/Ipl1 p kinase
family:
regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9, 454-
459). It
plays a major role in cell-cycle progression and has also been described as an
oncogene. It
maps to a chromosome region frequently amplified in tumours (Dutertre, S. et
al. (2002). On
the role of Aurora A in centrosome function. Oncogene 21, 6175-6183). It is
overexpressed
in a variety of human tumours, in particular breast and colon cancer, but has
limited
expression in normal tissues (Sen, S. et al. (1997). A putative
serine/threonine kinase
encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human
breast cancer cell lines. Oncogene 14, 2195-2200; Bischoff, J.R. et al.
(1998). A homologue
of Drosophila Aurora kinase is oncogenic and amplified in human colorectal
cancers. EMBO
J. 17, 3052-3065). Overexpression of active Aurora-A transforms rat
fibroblasts so that they
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
are capable of growing tumours in nude mice, while an inactive mutant is
unable to cause
oncogenic transformations. As an oncogenic protein kinase, Aurora-A is a
target for the
development of specific inhibitors that may be useful as cancer therapeutics.
Despite the
importance of Aurora-A for both cell division and cancer perspectives, little
is known at
present about its downstream targets and activation/deactivation mechanisms.
Several factors contribute to the activity of a serine/threonine kinase. These
include the
proper positioning of active site residues and the correct organisation of the
substrate-
binding site (the "activation segment"). Phosphorylation of a threonine
residue within the
activation segment is often required to elicit kinase activity and Aurora-A is
no exception.
Phosphorylation of a threonine in the Aurora-A activation segment (Thr288AUR,
human
numbering) is crucial for activity, although it is unclear as to whether it is
catalysed in vivo by
an upstream kinase or by Aurora-A itself (Bischoff, et al. (1999) supra).
Structural studies of
c-AMP dependent protein kinase (cAPK) have shown that when the corresponding
threonine
residue (Thr197~PK) is phosphorylated, the activation segment is in an active
conformation.
Cyclin-dependent kinases (CDKs) require not only phosphorylation of the
equivalent
threonine (Thr160~~K) but also the binding by a partner protein, cyclin-A, to
be fully activated.
Aurora-A might also rely on a similar mechanism. It has recently been reported
that in
vertebrates the interaction of Aurora-A with a partner protein, TPX2, leads to
a strong
activation of the kinase. Upon TPX2 binding, the in vitro autophosphorylation
activity of
Aurora-A is increased and dephosphorylation is prevented (Kufer et al., (2002)
supra).
ATP competitive inhibitors that are specific for different kinases are used as
therapeutic
agents in cancer treatment (Garcia-Echeverria, C., et al. (2000). ATP site-
directed
competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. 20,
28-57).
Although ATP-binding sites at the moment are the most common targets for the
design of
kinase inhibitors, it is difficult to achieve selectivity of such inhibitors
due to the similarity in
kinase active sites, which only have minor differences of surrounding amino-
acid residues
(Cheetham, G.M.T. et al. (2002). Crystal structure of Aurora-2, an oncogenic
serine-
threonine kinase. J. Biol. Chem. 277, 42419-42422).
The structure of unphosphorylated Aurora-A has been previously reported
(Cheetham,
G.M.T. et al. (2002). Crystal structure of Aurora-2, an oncogenic serine-
threonine kinase. J.
Biol. Chem. 277, 42419-42422; Nowakowski, J. et al. (2002). Structures of the
cancer-related
Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography.
Structure 10,
1659-1667). Further, WO 03/031606 describes the 3-dimensional crystal
structure of the
kinase catalytic domain of Aurora-A in a complex with the ATP analogue ATP-
PNP, and the
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
3-dimensional crystal structure ofi the kinase catalytic domain of Aurora-A in
complex with a
synthetic inhibitor. Aurora-A has the typical three-dimensional structure of
protein kinases,
with the active site situated between the N- and C-terminal lobe. Binding of
ATP involves
amino-acid residues that are conserved among all kinases. Extensive structural
work has
shown that kinases in their active state all assume a similar structural
framework, with the
'activation segment' in a similar conformation competent fior substrate
binding (Huse, M. and
Kuriyan, J. (2002). The conformational plasticity of protein kinases. Cell
109, 275-282).
However, they differ in the molecular mechanisms to achieve such an active
form. In the
case of Abl kinase, subtle differences in its activation mechanisms have been
exploited with
the development of the Abl-specific inhibitor Gleevec, which is used as a
leukaemia
therapeutic agent (Capdeville, R. et al. (2002). Glivec (STI571, imatinib), a
rationally
developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502).
In the case of Aurora-A, activation is achieved by both phosphorylation and by
the binding of
a specific activator, the protein TPX2 (Eyers, P.A., et al. (2003). A novel
mechanism for
activation of the protein kinase Aurora-A. Curr. Biol. 13, 691-697). Blocking
this activator-
binding site would provide a means to downregulate this kinase specifically.
In view thereof, it was an object of the present invention to elucidate the
structure of the
Aurora-A TPX2 binding site, to provide means for identifying compounds that
bind to Aurora-
A and preferably modulate Aurora-A activity, and to provide such compounds.
The present invention relates to (a) crystals of a fragment of phosphorylated
human Aurora-A
kinase alone (amino acid residues 122-403; hereinafter referred to as Aurora-
A(ON)), and (b)
crystals of said fragment of phosphorylated human Aurora-A kinase in complex
with a ligand,
i. e. an Aurora-A ligand complex. The Aurora-A ligand is a fragment of TPX2
which is a
minimal activating domain of TPX2. This minimal activating domain of TPX2
consists of
amino acid residues 1-43 of human TPX2 and hereinafter is referred to as
TPX2(1-43).
The present invention provides the structure coordinates of the phosphorylated
human
Aurora-A(~N) kinase. The complete coordinates are listed in Table A,
The present invention also provides the structure coordinates of the
phosphorylated human
Aurora-A(ON)/TPX2(1-43) complex. The complete coordinates are listed in Table
B.
The present invention also describes a method for determining at least a
portion of the three-
dimensional structure of molecules or molecular complexes which contain at
least some
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
4
structurally similar features to the Aurora-A TPX2 binding domain. It is
preferred that these
molecules or molecular complexes comprise at least a part of the ligand
binding site defined
by structure coordinates of Aurora-A amino acids Q127, W128, 8126, L159, F157,
E170,
L169, V206, Y199, H187, 8179, L178, V182, Y199, L188, 1184, V252, K250, P282,
H280
according to Table B, or a mutant or homologue thereof. The numbering system
as used
herein refers to the protein sequences for human Aurora-A.
The present invention also provides a machine-readable data storage medium
which
comprises a data storage material encoded with machine readable data defined
by the
structure coordinates of phosphorylated human Aurora-A(oN) kinase according to
Table A or
a homologue thereof, or of the phosphorylated human Aurora-A(ON)/TPX2(1-43)
complex
according to Table 8.
The present invention further provides a binding site in Aurora-A for an
Aurora-A ligand such
as TPX2 or fragments thereof, as well as methods for designing or selecting
further Aurora-A
ligands and in particular Aurora-A modulators including agonists, partial
agonists,
antagonists, partial antagonists of Aurora-A using information about the
crystal structures
disclosed herein.
The present invention further provides allosteric inhibitors of Aurora-A,
wherein at least a
portion of the inhibitor binds with any portion or all of residues Q127, W128,
8126, L159,
F157, E170, L169, V206, Y199, H187, 8179, L178, V182, Y199, L188, 1184, V252,
K250,
P282, H280 of Aurora-A according to Table B.
The present invention in particular relates to indole and indene derivatives
of formula (I)
R7 R1
R6
~ / ~~R2 ~I)
R 'X
R4 R3
wherein
R' represents hydrogen, alkylene-COR", alkylene-NHR8, alkylene-ORa, or
alkylene-SRB;
RZ represents hydrogen, alkylene-COR", alkylene-NHRB, alkylene-ORg, or
alkylene-SRe;
R3 represents hydrogen, alkyl, alkylene-R9, alkenylene-R9, alkynylene-R9, or
arylene-R9;
R4 represents hydrogen;
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
R5 represents hydrogen, alkyl, OR'°, NHR'°, SR'°,
alkylene-R'°, alkenylene-R'°,
alkynylene-R'°, or arylene-R'°;
R6 represents hydrogen, alkyl, OR'°, NHR'°, SR'°,
alkylene-R'°, alkenylene-R'°,
alkynylene-R'°, or arylene-R'°;
R' represents hydrogen;
R8 represents hydrogen, CO-alkyl, (aa)masp(aa)~, (aa)mglu(aa)~, or
(aa)mcys(aa)n, or
optionally substituted alkyl, aryl or heteroaryl;
R9 represents NH-alkyl, N(alkyl)2, N+(alkyl)3, optionally substituted aryl, or
optionally
substituted heteroaryl;
R'° represents hydrogen or a mono- or bicyclic, saturated, partially
unsaturated or
aromatic, alicyelic or heterocyclic radical which may be substituted;
R" represents hydrogen, alkyl or haloalkyl;
X represents a nitrogen atom or CH;
as represents an amino acid radical; and
n is zero or an integer of 1 to 10;
m is zero or an integer of 1 to 10,
provided that R' and RZ are not both hydrogen and that R5 and R6 are not both
hydrogen,
and optical isomers, physiologically acceptable salts, derivatives and
prodrugs thereof.
The present invention also relates to the pharmaceutical compostions
containing Aurora-A
ligands, such as said indole and indene derivatives, and the use of Aurora-A
ligands, such as
said indole and indene derivatives, in therapy, in particular in cancer
treatment.
In the drawings the figures show as
(figure 1 ) (A) anti-Xenopus TPX2 Western blot (upper panel) and anti-Xenopus
Aurora-
A Western blot (lower panel) of GST (glutathione S transferase) (lanes 1 and
2), GST Xenopus TPX2 (lanes 3 and 4) or GST Xenopus TPX2(1-39) (lanes 5
and 6) which proteins were incubated in Xenopus cytostatic factor (CSF)
arrested extracts in the presence or absence of RanQ69L-GTP and
immunoprecipitated with GST antibody-coated beads;
(B) anti-GST Western blot (upper panel) and anti-human Aurora-A Western
blot (lower panel) of GST (lane 1 ), GST TPX2(1-43) (lane 2) or GST TPX2(15-
43) (lane 3) proteins that were incubated in mitotic HeLa cell extract and
immunoprecipitated with GST antibody-coated beads;
(C) autoradiography of the SDS-PAGE gel (left panel) and the corresponding
Coomassie-stained gel (right panel) after in vitro phosphorylation (y32P-ATP)
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
of histone H3 by human Aurora-A in the presence of full-length TPX2, GST
TPX2(1-43) or GST TPX2(15-43) (lanes 2, 3 and 4 respectively);
(D) much of the phosphorylation signal in GST after in vitro phosphoryiation
(YszP-ATP) of TPX2(1-43) by Aurora-A (lane 1) followed by TEV cleavage
(lane 2);
(E) an anti-human Aurora-A Western blot (upper panel) and an anti-
phosphoAurora-A Western blot (lower panel) after phosphatase PP1
treatment of human Aurora-A in the absence or presence of full-length TPX2,
GST TPX2(1-43) or GST TPX2(15-43) followed by detection of Aurora-A by a
polyclonal antibody (upper panel) and an antibody specific for Aurora-A
phosphorylated at Thr288AUR (lower panel);
(figure 2) (A) an in vitro pull-down assay with respect to the binding of full-
length
Aurora-A, AuroraoN or AuroraON(D274N) to GST TPX2(1-43) (lanes 4,
and 6), and to GST (lanes 1, 2 and 3);
(B) an anti-phospho Aurora-A Western blot of wild-type Aurora(ON) and the
D274N mutant when expressed in E. coli.
(C) autoradiograph for detecting in vitro phosphorylation of histone H3 by
Aurora(~N) in the presence or absense of TPX2(1-43) (lane 2 compared to
lane 1), the cleaved (lane 2) or uncleaved (lane 3) GST TPX2(1-43) fusion
protein;
(D) Sequence alignment of TPX2 N-terminal domain from human (I~,
Xenopus (X) and puffer fish (F), secondary structure elements being shown
above the sequences in red (upstream extended stretch) and pink
(downstream helical stretch), and intervening residues not modelled being
marked with a dotted line;
(E) Sequence alignment of Aurora-A kinase catalytic domain from three
vertebrate species that contain TPX2 (human, H.AUR-A; Xenopus, ~CAUR-A;
puffer fish, F.AUR-A), two invertebrates that do not contain TPX2 (Drosophila,
D.AUR-A; C.elegans, C.AUR-A) together with human and Xenopus Aurora-B
(H.AUR-B, X.AUR-B) and vertebrate cAPK, wherein Aurora-A secondary
structural elements are labelled above the alignment, the phosphorylated
Thr288 (human numbering) is shown, and residues that interact with 7-21TPx
or 30-43TPx being indicated by filled or open circles respectively;
(figure 3) ribbon style drawings of the structure of Aurora-A bound to TPX2 as
(A) a view of the complex between the catalytic domain of human Aurora
(AuroraON) and the N-terminal domain of TPX2 shown in typical kinase
orientation, an upstream stretch of TPX2 binding at the N-terminal lobe of
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
Aurora-A, and a downstream stretch binding between the two lobes, and a
dotted line marking the approximate path of the linker connecting the two
TPX2 stretches (disordered and not modeled);
(B) a view of the complex after a 180° rotation about the vertical axis
in
respect to view in panel A showing more clearly the two stretches of TPX2
that bind to Aurora-A;
(C) the upstream stretch of TPX2 (residues 7-21TPX) that binds at a
hydrophobic surface groove present in the N-terminal lobe of the kinase,
wherein details of the extensive interactions are shown in the same
orientation
as in panel B;
(D) the downstream helical stretch of TPX2 (residues 30-43TPx) that binds
Aurora-A near helix aC and the activation segment, close to but not directly
in
contact with phospho-Thr288AUR, wherein details of interactions being shown
in the same orientation as in panel B and C.
(figure 4) ribbon style drawings of conformational states of phosphorylated
Aurora-A in
the presence and absence of TPX2 as
(A) an overlay showing that the structures of Aurora-A when bound to TPX2
and when unbound are closely superposable at the position of active site
residues and of helix aC, but diverge at the activation segment between
residues His280AUR and Leu293AUR, wherein Phospho-Thr288AUR points
inwards in the TPX2-bound structure and outwards in the kinase alone
structure;
(B) an illustration of conformational changes upon TPX2 binding, according to
which the activation segments of the kinase alone structure (left panel) and
of
the TPX2-bound structure (right panel) are shown in a view rotated by
approximately 90° with respect to panel A, and TPX2 binding results in
the
reorganization of the activation segment, with a 10 A movement of Thr288AUR;
(C) a schematic representation of the molecular mechanism of TPX2-mediated
activation of Aurora-A, according to which the upstream stretch of TPX2
anchors the regulator to the N-terminal lobe of the kinase and the downstream
stretch (helix) hooks the activation segment triggering a lever-arm like
movement, where rotations at His280AUR and Pro282AU~ pull on Thr288AUR;
(figure 5) the structure coordinates of phosphorylated human Aurora-A(dN)
kinase
(table A);
(figure 6) the structure coordinates of phosphorylated human Aurora-
A(~N)/TPX2(1-43)
complex (table B).
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
Using X-ray crystallography, crystal structures of phosphorylated human Aurora-
A(ON) alone
at 2.75 A resolution and in complex with a minimal activating domain of TPX2
at 2.5 A
resolution have been determined and the specific site of TPX2-mediated
activation of Aurora-
A has been found. TPX2 binds at two sites on the kinase. One stretch of TPX2
(residues 8-
19) binds at the N-terminal lobe of the kinase and another stretch (31-38)
binds between the
two lobes at the phosphorylated activation segment, positioning it for
substrate binding. The
TPX2-binding site located on the N-terminal lobe of the kinase consists of an
extended
surface groove formed by Aurora-specific residues. The groove consists of two
pockets, one
shaped by residues E170, L169, V206, 8179, L178, V182, Y199 and the other
shaped by
residues Q127, W128, 8126, L159 and F157. The two pockets are occupied by
hydrophobic
side chains of TPX2, Y8, Y10, A12 and P13 on one side, and F16, f17 and F19 on
the other.
From the structure and biochemical data it is concluded that binding of this
TPX2 stretch is
necessary but not sufficient for activation of Aurora-A, allowing the
downstream TPX2 stretch
to bind with enough affinity to achieve activation. Binding of a small-
molecule inhibitor to the
TPX2-recognition groove on the N-terminal lobe of Aurora-A would decrease the
activity of
this kinase by blocking its specific activation mechanism.
The Aurora-A kinase and the TPX2 protein described herein are intended to
include any
polypeptide which has the activity of the naturally occurring Aurora-A kinase
and TPX2
protein, respectively. Aurora-A and TPX2 contemplated herein include all
vertebrate and
mammalian forms such as rat, mouse, pig, goat, horse, guinea pig, rabbit,
monkey,
orangutan and human. Such terms also include polypeptides that differ from
naturally
occurring forms of Aurora-A kinase and TPX2 protein by having amino acid
deletions,
substitutions, and additions, but which retain the activity of Aurora-A kinase
and TPX2
protein, respectively. Particular Aurora-A sequences are shown in figure 2E
and particular
TPX2 sequences are shown in figure 2D. According to the present invention, the
human
sequences are preferred.
The crystal structures of the invention preferably contains at least 25%, more
preferably at
least 50%, more preferably at least 75%, more preferably at least 90%, more
preferably at
least 95°!°, more preferably at least 99%, and most preferably
all of the coordinates listed in
Table A and Table B, respectively.
The crystal of the phosphorylated human Aurora-A(ON) kinase of the invention
preferably
has the following unit cell dimensions in angstroms: a = 81.18 ~ 5%, b = 81.18
~ 5%, c =
169.62 ~ 5% and the space group P6~22.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
The crystal of the phosphorylated human Aurora-A(~N) kinase/TPX2(1-43) complex
of the
invention preferably has the following unit cell dimensions in angstroms: a =
59.63 ~ 5%, b =
81.72 ~ 5%, c = 83,05 ~ 5% and an orthorhombic space group P2~2~2~.
The three-dimensional structure of the phosphorylated human Aurora-A(ON)
kinase and of
the phosphorylated human Aurora-A(dN) kinase/TPX2(1-43) complex of this
invention are
defined by a set of structure coordinates as set forth in Table A and Table B,
respectively.
The term "structure coordinates" refers to Cartesian coordinates derived from
mathematical
equations related to the patterns obtained on diffraction of a monochromatic
beam of X-rays
by the atoms (scattering centers) of the protein or protein complex in crystal
form. The
diffraction data are used to calculate an electron density map of the
repeating unit of the
crystal. The electron density maps are then used to establish the positions of
the individual
atoms of the complex.
Those of skill in the art will understand that a set of structure coordinates
for a kinase or a
kinase/ligand complex or a fragment thereof, is a relative set of points that
define a shape in
three dimensions. Thus, it is possible that an entirely different set of
coordinates could define
a similar or identical shape. Moreover, slight variations in the individual
coordinates will have
little effect on overall shape.
The variations in coordinates discussed above may be generated because of
mathematical
manipulations of the structure coordinates. For example, the structure
coordinates set forth in
Table A could be manipulated by crystallographic permutations of the structure
coordinates,
fractionalization of the structure coordinates; integer additions or
subtractions to sets of the
structure coordinates, inversion of the structure coordinates or any
combination of the above.
Alternatively, modifications in the crystal structure due to mutations,
additions, substitutions,
andlor deletions of amino acids, or other changes in any of the components
that make up the
crystal could also account for variations in structure coordinates. If such
variations are within
an acceptable standard error as compared to the original coordinates, the
resulting three-
dimensional shape is considered to be the same.
Various computational analyses are therefore necessary to determine whether a
molecule or
molecular complex or a portion thereof is sufficiently similar to all or parts
of the kinase or the
kinase/ligand complex described above as to be considered the same. Such
analyses may
be carried out in current software applications, such as the Molecular
Similarity application of
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
QUANTA (Molecular Simulations Inc., San Diego, CA) version 4.1, and as
described in the
accompanying User's Guide.
The Molecular Similarity application permits comparisons between different
structures,
different conformations of the same structure, and different parts of the same
structure. The
procedure used in Molecular Similarity to compare structures is divided into
four steps: 1)
load the structures to be compared; 2) define the atom equivalences in these
structures; 3)
perform a fitting operation; and 4) analyze the results.
Each structure is identified by a name. One structure is identified as the
target (i. e., the fixed
structure); all remaining structures are working structures (i. e., moving
structures). Since
atom equivalency within QUANTA is defined by user input, for the purpose of
this invention
equivalent atoms are defined as protein backbone atoms (N, C and O) for all
conserved
residues between the two structures being compared. Also, only rigid fitting
operations are
considered.
When a rigid fitting method is used, the working structure is translated and
rotated to obtain
an optimum fit with the target structure. The fitting operation uses an
algorithm that computes
the optimum translation and rotation to be applied to the moving structure,
such that the root
mean square difference of the fit over the specified pairs of equivalent atom
is an absolute
minimum. This number, given in angstroms, is reported by QUANTA.
For the purpose of this invention, any molecule or molecular complex that has
a root mean
square deviation of conserved residue backbone atoms (N, C, O) of less than
1.5 A when
superimposed on the relevant backbone atoms described by structure coordinates
listed in
Table A or Table B are considered identical. More preferably, the root mean
square deviation
is less than 1.0 A. In a preferred embodiment of the present invention, the
molecule or
molecular complex comprises at least a portion of the ligand binding site
defined by structure
coordinates of Aurora-A amino acids Q127, W128, 8126, L159, F157, E170, L169,
V206,
Y199, H187, 8179, L178, V182, Y199, L188, 1184, V252, K250, P282, H280
according to
Table B, or a mutant or homologue of said molecule or molecular complex. More
preferred
are molecules or molecular complexes comprising all or any part of the ligand
binding site
defined by structure coordinates of Aurora-A amino acids Y199, L178, W128,
H187, L188,
1184 according to Table B, or a mutant or homologue of said molecule or
molecular complex.
The term "complex" or "molecular complex" means Aurora-A or a mutant or
homologue of
Aurora-A in a covalent or non-covalent association with a chemical entity or
compound.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
11
For purposes of the present invention, by "at least a portion of" it is meant
all or any part of
the ligand binding site defined by these structure coordinates.
By "mutant or homologue" as used herein it is meant a molecule or molecular
complex
having a similar structure andlor sequences to Aurora-A or TPX2. By "similar
structure" it is
meant a mutant or homologue having a binding pocket or binding domain that
have a root
mean square deviation from the backbone atoms of said Aurora-A or TPX2 amino
acids of
not more than 1.5 Angstroms. By "similar sequence" it is meant a mutant or
homologue
having 30%, or more preferably 75%, identity with Aurora-A or TPX2 over an
amino acid
sequnce of at least 30, preferably at least 50, in particular at least 100 and
especially at least
200 consecutive amino acid.
The term "root mean square deviation" means the square root of the arithmetic
mean of the
squares of the deviations from the mean. It is a way to express the deviation
or variation from
a trend or object. For purposes of this invention, the "root mean square
deviation" defines the
variation in the backbone of a protein or protein complex from the relevant
portion of the
backbone of the Aurora-A fragment of the complex as defined by the structure
coordinates
described herein.
Once the structure coordinates of a protein crystal have been determined they
are useful in
solving the structures of other crystals.
Thus, in accordance with the present invention, the structure coordinates of
the kinase of the
kinase/ligand complex, and portions thereof is stored in a machine-readable
storage
medium. Such data may be used for a variety of purposes, such as drug
discovery and x-ray
crystallographic analysis of protein crystals.
Accordingly, in one embodiment of this invention is provided a machine-
readable data
storage medium comprising a data storage material encoded with the structure
coordinates
set forth in Table A and/or with the structure coordinates set forth in Table
B.
For the first time, the present invention permits the use of structure-based
or rational drug
design techniques to design, select, and synthesize chemical entities,
including inhibitory and
stimulatory compounds that are capable of binding to Aurora-A, or any portion
thereof.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
12
One particularly useful drug design technique enabled by this invention is
iterative drug
design. Iterative drug design is a method for optimizing associations between
a protein and a
compound by determining and evaluating the three-dimensional structures of
successive
sets of protein/compound complexes.
Those of skill in the art will realize that association of natural ligands or
substrates with the
binding pockets of their corresponding kinases or enzymes is the basis of many
biological
mechanisms of action. The term "binding pocket" as used herein, refers to a
region of a
molecule or molecular complex, that, as a result of its shape, favorably
associates with
another chemical entity or compound. Similarly, many drugs exert their
biological effects
through association with the binding pockets of kinases and enzymes. Such
associations
may occur with all or any parts of the binding pockets. An understanding of
such associations
will help lead to the design of drugs having more favorable associations with
their target
kinase, and thus, improved biological effects. Therefore, this information is
valuable in
designing potential ligands or modulators, e.g. inhibitors, of Aurora-A
kinase.
The term "associating with" refers to a condition of proximity between
chemical entities or
compounds, or portions thereof. The association may be non-covalent--wherein
the
juxtaposition is energetically favored by hydrogen bonding or van der Waals or
electrostatic
interactions--or it may be covalent.
In iterative drug design, crystals of a series of protein/compound complexes
are obtained and
then the three-dimensional structures of each complex is solved. Such an
approach provides
insight into the association between the proteins and compounds of each
complex. This is
accomplished by selecting compounds with inhibitory activity, obtaining
crystals of this new
protein/compound complex, solving the three-dimensional structure of the
complex, and
comparing the associations between the new protein/compound complex and
previously
solved protein/compound complexes. By observing how changes in the compound
affected
the protein/compound associations, these associations may be optimized.
In some cases, iterative drug design is carried out by forming successive
protein-compound
complexes and then crystallizing each new complex. Alternatively, a pre-formed
protein
crystal is soaked in the presence of a compound, thereby forming a
protein/compound
complex and obviating the need to crystallize each individual protein/compound
complex.
As used herein, the term "soaked" refers to a process in which the crystal is
transferred to a
solution containing the compound of interest.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
13
The structure coordinates set forth in Table A and Table B can also be used to
aid in
obtaining structural information about another crystallized molecule or
molecular complex.
This may be achieved by any of a number of well-known techniques, including
molecular
replacement.
The structure coordinates set forth in Table A and Table B can also be used
for determining
at least a portion of the three-dimensional structure of molecules or
molecular complexes
which contain at least some structurally similar features to Aurora-A. In
particular, structural
information about another crystallized molecule or molecular complex may be
obtained. This
may be achieved by any of a number of well-known techniques, including
molecular
replacement.
Therefore, in another embodiment this invention provides a method of utilizing
molecular
replacement to obtain structural information about a crystallized molecular
complex whose
structure is unknown comprising the steps of:
a) generating an X-ray diffraction pattern from said crystallized molecular
complex;
b) applying at least a portion of the structure coordinates set forth in Table
A and Table
B to the X-ray diffraction pattern to generate a three-dimensional electron
density
map of the molecular complex whose structure is unknown; and
c) using all or a portion of the structure coordinates set forth in Table A
and Table B to
generate homology models of Aurora-A or any other kinase ligand binding
domain.
Preferably, the crystallized molecular complex is obtained by soaking a
crystal of this
invention in a solution.
Molecular replacement provides an accurate estimation of the phases for an
unknown
structure. Phases are a factor in equations used to solve crystal structures
that can not be
determined directly. Obtaining accurate values for the phases, by methods
other than
molecular replacement, is a time-consuming process that involves iterative
cycles of
approximations and refinements and greatly hinders the solution of crystal
structures.
However, when the crystal structure of a protein containing at least a
homologous portion
has been solved, the phases from the known structure provide a satisfactory
estimate of the
phases for the unknown structure.
Thus, this method involves generating a preliminary model of a molecule or
molecular
complex whose structure coordinates are unknown, by orienting and positioning
the relevant
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
14
portion of the Aurora-A ligand complex according to Table B within the unit
cell of the crystal
of the unknown molecule or molecular complex so as best to account for the
observed X-ray
diffraction pattern of the crystal of the molecule or molecular complex whose
structure is
unknown. Phases can then be calculated from this model and combined with the
observed
X-ray diffraction pattern amplitudes to generate an electron density map of
the structure
whose coordinates are unknown. This, in turn, can be subjected to any well-
known model
building and structure refinement techniques to provide a final, accurate
structure of the
unknown crystallized molecule or molecular complex [E. Lattman,"Use of the
Rotation and Translation Functions", in Meth. Enzymol., 115, pp. 55-77 (1985);
M. G.
Rossmann, ed.,"The Molecular Replacement Method", Int. Sci. Rev. Set., No. 13,
Gordon &
Breach, New York (1972)].
The structure of any portion of any crystallized molecule or molecular
complex, or mutant, or
homologue that is sufficiently homologous to any portion of the Aurora-A
ligand complex can
be solved by this method.
The structure coordinates are also particularly useful to solve the structure
of crystals of
Aurora-A ligand co-complexed with a variety of chemical entities. This
approach enables the
determination of the optimal sites for interaction between chemical entities,
including
interaction of candidate Aurora-A modulators, e.g. inhibitors with the
complex. For example,
high resolution X-ray diffraction data collected from crystals exposed to
different types of
solvent allows the determination of where each type of solvent molecule
resides. Small
molecules that bind tightly to these sites can then be designed and
synthesized and tested
for their Aurora-A modulation, e.g. inhibition activity.
All of the complexes referred to above may be studied using well-known X-ray
diffraction
techniques and may be refined versus 1.5-3 A resolution X-ray data to an R
value of about
0.20 or less using computer software, such as X-PLOR [Yale University, 1992,
distributed by
Molecular Simulations, Inc.; see, e, g., Blundell & Johnson, supra; Meth.
Enzymol., vol. 114
& 115, H. W. Wyckoff et al., eds., Academic Press (1985)]. This information
may thus be
used to optimize Aurora-A agonists, partial agonists, antagonists, partial
antagonists, and
more importantly, to design new Aurora-A agonists/antagonists.
Accordingly, the present invention is also directed to a binding site in
Aurora-A for an Aurora-
A ligand in which a portion of Aurora-A ligand is in van der Walls contact or
hydrogen
bonding contact with at least one of the following residues: Y199, L178, W128,
L159, H187,
L188, 1184 of Aurora-A.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
For purposes of this invention, by Aurora-A binding site it is also meant to
include mutants or
homologues thereof. In a preferred embodiment, the mutants or homologues have
at least
25% identity, more preferably 50% identity, more preferably 75% identity, and
most
preferably 95% identity to residues Q127, W128, 8126, L159, F157, E170, L169,
V206,
Y199, H187, 8179, L178, V182, Y199, L188, 1184, V252, K250, P282, H280 of
Aurora-A
binding sites.
The present invention is also directed to a machine-readable data storage
medium,
comprising a data storage material encoded with machine readable data, wherein
the data is
defined by the structure coordinates of an Aurora-A ligand complex according
to Table B or a
homologue of said complex, wherein said homologue comprises backbone atoms
that have
a root mean square deviation from the backbone atoms of the complex of not
more than 3.0
A, preferably of not more that 2.0 A.
The present invention also provides for computational methods using three-
dimensional
models of the Aurora-A kinase that are based on crystals of the kinase or the
kinase ligand
complex. Generally, the computational method of designing an Aurora-A ligand
determines
which amino acid or amino acids of Aurora-A interact with a chemical moiety
(at lease one)
of the ligand using a three-dimensional model of a crystallized protein
comprising the Aurora-
A kinase with a bound ligand and selecting a chemical modification (at least
one) of the
chemical moiety to produce a second chemical moiety with a structure that
either decreases
or increases an interaction between the interacting amino acid and the second
chemical
moiety compared to the interaction between the interacting amino acid and the
corresponding chemical moiety on the natural ligand, i.e. TPX2 or a fragment
thereof.
The computational methods of the present invention are for designing kinase
synthetic
ligands using such crystal and three dimensional structural information to
generate synthetic
ligands that modulate the conformational changes of the kinase. These
computational
methods are particularly useful in designing an agonist, partial agonist,
antagonist or partial
antagonist to the kinase, wherein the agonist, partial agonist, antagonist or
partial antagonist
has an extended moiety that prevents any one of a number of ligand-induced
molecular
events that alter the kinase's influence on one of its targets, such as
preventing the normal
coordination of the activation domain observed for a naturally occurring
ligand or other
ligands that mimic the naturally occurring ligand, such as an agonist. As
described herein,
synthetic ligands of the kinase will be useful in modulating kinase activity
in a variety of
medical conditions.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
16
Aurora-A is known to comprise various segments as follows: 1) an amino-
terminal ligand-
binding site; and 2) an Aurora-A activation segement.
This modularity permits different segments and sites of each protein to
separately
accomplish different functions, although the segments and sites influence each
other.
Exploiting the TPX2-binding site in the N-terminal lobe of Aurora-A has the
advantage of
blocking the activation of this oncogenic kinase and of blocking it
specifically. An Aurora-A
specific inhibitor would be an important cancer therapeutic agent in
particular for breast and
colon tumours.
The polypeptides referred to herein (e. g., Aurora-A, TPX2, and the like) may
be produced by
any well-known method, including synthetic methods, such as solid phase,
liquid phase and
combination solid phase/liquid phase syntheses; recombinant DNA methods,
including cDNA
cloning, optionally combined with site directed mutagenesis; and/or
purification of the natural
products, optionally combined with enzymatic cleavage methods to produce
fragments of
naturally occurring forms of Aurora-A and TPX2. The peptides can be expressed,
crystallized, its three dimensional structure determined with a ligand bound
(either using
crystal data from the same kinase or a different kinase or a combination
thereof), and
computational methods used to design ligands to its ligand binding site,
particularly ligands
that contain an extension moiety that coordinates the activation segment of
Aurora-A.
Typically Aurora-A and TPXZ as well as fragments thereof are purified to
homogeneity for
crystallization.
Purity of Aurora-A is measured with SDS-PAGE, mass spectrometry and
hydrophobic HPLC.
The purified Aurora-A for crystallization should be at least 97.5 % pure or
97.5%, preferably
at least 99.0% pure or 99.0% pure, more preferably at least 99.5% pure or
99.5% pure.
Initially purification of the unliganded kinase can be obtained by
conventional techniques,
such as size exclusion chromatography, hydrophobic interaction chromatography
(HPLC),
ion exchange chromatography (HPLC), and heparin affinity chromatography.
To achieve higher purification for improved crystals of Aurora-A, it will be
desirable to ligand
shift purify the kinase using a column that separates the kinase according to
charge, such as
an ion exchange or hydrophobic interaction column, and then bind the eluted
kinase with a
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
17
ligand, especially an agonist or partial agonist. The ligand induces a change
in the kinase's
surface charge such that when rechromatographed on the same column, the kinase
then
elutes at the position of the liganded kinase are removed by the original
column run with the
unliganded kinase. Usually saturating concentrations of ligand are used in the
column and
the protein can be preincubated with the ligand prior to passing it over the
column.
More recently developed methods involve engineering a "tag" such as with
histidine placed
on the end of the protein, such as on the amino terminus, and then using a
nickle chelation
column for purification, Janknecht R., Proc. Natl. Acad. Sci. USA Vol 88: 8972-
8976 (1991)
incorporated by reference.
Typically, purified Aurora-A is equilibrated at a saturating concentration of
ligand at a
temperature that preserves the integrity of the protein. Ligand equilibration
can be stablished
between 2 and 37 °C, although the kinase tends to be more stable in the
2-20 °C range.
Preferably crystals are made with the hanging and/or sittiing drop methods.
Regulated temperature control is desirable to improve crystal stability and
quality.
Temperatures between 4 and 25 °C are generally used and it is often
preferable to test
crystallization over a range of temperatures. It is preferable to use
crystallization
temperatures from 18 to 25 °C, more preferably 20 to 23 °C, and
most preferably 22 °C.
The Aurora-A ligand of this invention is any peptide, peptide mimetic or
nonpeptide, including
small organic molecules, that is capable of acting as a ligand for Aurora-A.
In a preferred
embodiment, the Aurora-A ligand is an Aurora-A modulator. By" Aurora-A
modulator " it is
meant an agonist or activator, a partial agonist or partial activator, an
antagonist or inhibitor,
or a partial antagonist or partial inhibitor of the Aurora-A kinase.
Agonists or partial agonists induce changes in kinases that place them in an
active
conformation that allows them to influence one of its targets. There may be
several different
ligand-induced changes in the kinase's conformation.
Antagonists or partial antagonists bind to kinases, but fail to induce
conformational changes
that alter the kinase's target-influencing properties or physiologically
telcram conformations.
Binding of an antagonist or partial antagonist can also block the binding and
therefore the
actions of an agonist or partial agonist.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
18
Partial agonists, or partial antagonists, bind to kinases and induce only part
of the changes in
the kinases that are induced by agonists or antagonists, respectively. The
differences can be
qualitative or quantitative. Thus, a partial agonist or partial antagonist may
induce some of
the conformation changes induced by agonists or antagonists, respectively, but
not others, or
it may only induce certain changes to a limited extent.
As described herein, the unliganded kinase is in a configuration that is
either inactive, has
some activity or has phosphorylating activity. Binding of agonist ligands
induces
conformational changes in the kinase such that the kinase becomes more active
and/or is
protected from deactivation, in particular from dephosphorylation.
According to a particular embodiment, the present invention relates to
allosteric inhibitors of
Aurora-A. The binding of such an allosteric inhibitor to Aurora-A results in a
conformational
change of the kinase, thereby decreasing the kinases's activity, preferably by
blocking its
activation mechanism. The preferred binding site of an allosteric inhibitor
according to the
present invention is the TPX2-recognition groove where TPX2 binds Aurora-A, as
described
herein.
Consequently, an extended chemical moiety (or more) from the ligand that
stabilizes the
binding or contact of the TPX2 binding site with the binding site of Aurora-A
can be designed.
Typically such chemical moieties will extend past and away from the molecular
recognition
domain on the ligand and usually past the buried binding cavity of the ligand.
Ligand binding by the kinase is a dynamic process, which regulates kinase
function by
inducing an altered conformation.
The three-dimensional structure of the liganded Aurora-A kinase can be used in
the
development of new Aurora-A synthetic ligands. In addition, Aurora-A is
overall well suited to
modern methods including three-dimensional structure elucidation and
combinatorial
chemistry such as those disclosed in EP 335 628, U. S. patent 5,463,564, which
are
incorporated herein by reference. Computer programs that use crystallography
data when
practicing the present invention enable the rational design of ligands to
Aurora-A. Programs
such as RASMOL can be used with the atomic coordinates from crystals generated
by
practicing the invention or used to practice the invention by generating three
dimensional
models and/or determining the structures involved in ligand binding. Computer
programs
such as INSIGHT and GRASP allow for further manipulation and the ability to
introduce new
structures. In addition, high throughput binding and bioactivity assays can be
devised using
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
19
purified recombinant protein and modern assays described herein and known in
the art in
order to refine the structure of a ligand and thereby the activity.
Generally the computational method of designing an Aurora-A synthetic ligand
comprises
two steps:
1 ) determining which amino acid or amino acids of Aurora-A interacts with a
first
chemical moiety (at least one) of the ligand using a three dimensional model
of a
crystallized protein comprising Aurora-A with a bound ligand; and
2) selecting chemical modifications (at least one) of the first chemical
moiety to produce
a second chemical moiety with a structure to either decrease or increase an
interaction between the interacting amino acid and the second chemical moiety
compared to the interaction between the interacting amino acid and the first
chemical
moiety.
Preferably the method is carried out wherein said three dimensional model is
generated by
comparing isomorphous ligand derivatives to produce improved phasing. Further
preferred is
wherein said method comprises determining a change in interaction between said
interacting
amino acid and said ligand after chemical modification of said first chemical
moiety,
especially wherein said three dimensional model is generated by comparing
isomorphous
ligand derivatives to produce improved phasing. Also preferred is wherein said
selecting
uses said first chemical moiety that interacts with at least one of the
interacting amino acids
Y199, L178, W128, L159, H187, L188, 1184.
As shown herein, interacting amino acids form contacts with the ligand and the
center of the
atoms of the interacting amino acids are usually 2 to 4 angstroms away from
the center of
the atoms of the ligand. Generally these distances are determined by computer,
however
distances can be determined manually once the three dimensional model is made.
See also
Wagner et al., Nature 378 (6558): 670-697 (1995) for stereochemical figures of-
three
dimensional models. More commonly, the atoms of the ligand and the atoms of
interacting
amino acids are 3 to 4 angstroms apart. The invention can be practiced by
repeating steps I
and 2 to refine the fit of the ligand to the ligand bindiung site and to
determine a better ligand,
such as an agonist, partial agonist, antagonist or partial antagonist.
The three dimensional model of Aurora-A can be represented in two dimensions
to
determine which amino acids contact the ligand and to select a position on the
ligand for
chemical modification and changing the interaction with a particular amino
acid compared to
that before chemical modification. The chemical modification may be made using
a
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
computer, manually using a two dimensional representation of the three
dimensional model
or by chemically synthesizing the ligand. The ligand can also interact with
distant amino
acids after chemical modification of the ligand to create a new ligand.
Distant amino acids
are generally not in contact with the ligand before chemical modification. A
chemical
modification can change the structure of the ligand to make a new ligand that
interacts with a
distant amino acid usually at least 4.5 angstroms away from the ligand,
preferably wherein
said first chemical moiety is 6 to 12 angstroms away from a distant amino
acid. Often distant
amino acids will not line the surface of the binding cavity for the ligand,
they are too far away
from the ligand to be part of a pocket or binding cavity. The interaction
between an amino
acid of the ligand binding site and an atom of a ligand can be made by any
force or attraction
described in nature. Usually the interaction between the atom of the amino
acid and the
ligand will be the result of a hydrogen bonding interaction, charge
interaction, hydrophobic
interaction, van der Waals interaction or dipole interaction. In the case of
the hydrophobic
interaction it is recognized that this is not a per se interaction between the
amino acid and
ligand, but rather the usual result, in part, of the repulsion of water or
other hydrophilic group
from a hydrophobic surface. Reducing or enhancing the interaction of the
ligand binding site
and a ligand can be measured by calculating or testing binding energies,
computationally or
using thermodynamic or kinetic methods as known in the art.
Chemical modifications will often enhance or reduce interactions of an atom of
an amino acid
of the ligand binding site and an atom of a ligand. Steric hindrance will be a
common means
of changing the interaction of the ligand binding cavity with the activation
segment.
The present invention also provides methods for identifying compounds that
modulate kinase
activity. Various methods or combinations thereof can be used to identify
these compounds.
For example, test compounds can be modeled that fit spatially into the Aurora-
A ligand
binding site as defined by structure coordinates according to Table B, or
using a three-
dimensional structural model of Aurora-A, mutant Aurora-A or Aurora-A homolog
or portion
thereof. Structure coordinates of the ligand binding site, in particular amino
acids Q127,
W128, 8126, L159, F157, E170, L169, V206, Y199, H187, 8179, L178, V182, Y199,
L188,
1184, V252, K250, P282, H280 can also be used to identify structural and
chemical features.
Identified structural or chemical features can then be employed to design or
select
compounds as potential Aurora-A modulators. By structural and chemical
features it is meant
to include, but is not limited to, van der Waals interactions, hydrogen
bonding interactions,
charge interaction, hydrophobic bonding interaction, hydrophobic interaction
and dipole
interaction. Alternatively, or in conjunction, the three-dimensional
structural model or the
ligand binding site can be employed to design or select compounds as potential
Aurora-A
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
21
modulators. Compounds identified as potential Aurora-A modulators can then be
synthesized
and screened in an assay characterized by binding of a test compound to the
Aurora-A.
Examples of assays useful in screening of potential Aurora-A modulators
include, but are not
limited to, screening in silico, in vitro assays and high throughput assays,
for instance, based
on phosphorylation of histone H3 as described herein (Crosio, C., Fimia, G.
M., Loury, R.,
Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C. D., and Sassone-Corsi, P.
(2002). Mitotic
phosphorylation of Histone H3: spatio-temporal regulation by mammalian Aurora
kinases.
Mol. Cell Biol. 22, 874-885).
A preferred method of the invention can be described as a computational method
of
designing an kinase antagonist from an kinase agonist comprising:
1) determining a structure of a molecular recognition site of said agonist
using a three
dimensional model of a crystallized protein comprising an Aurora-A, and
2) selecting at least one chemical modification of said agonist that provides
a ligand
structure that extends beyond a binding site for said agonist and in the
direction of at
least one protein site important in Aurora-A biological function.
Another preferred method of the invention can be described as a computational
method of
designing a selective kinase modulator such as an kinase super agonist or
antagonist
comprising:
1) determining at least one interacting amino acid of an Aurora-A that
interacts with at
least one first chemical moiety of said ligand using a three dimensional model
of a
crystallized protein comprising Aurora-A with a bound ligand, and
2) selecting at least one chemical modification of said first chemical moiety
to produce a
second chemical moiety with a structure to reduce or enhance an interaction
between
said interacting amino acid and said second chemical moiety compared to said
interaction between said interacting amino acid and said first chemical
moiety.
However, as will be understood by those of skill in the art upon this
disclosure, other
structure based design methods can be used. Various computational structure
based design
methods have been disclosed in the art.
For example, a number computer modeling systems are available in which the
sequence of
the Aurora-A and the Aurora-A structure (i. e., atomic coordinates of Aurora-A
andlor the
atomic coordinates of the active site, the bond and dihedral angles, and
distances between
atoms in the active site such as provided in Table A and Table B) can be
input. This
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
22
computer system then generates the structural details of the site in which a
potential Aurora-
A modulator binds so that complementary structural details of the potential
modulators can
be determined. Design in these modeling systems is generally based upon the
compound
being capable of physically and structurally associating with Aurora-A. In
addition, the
compound must be able to assume a conformation that allows it to associate
with Aurora-A.
Some modeling systems estimate the potential inhibitory or binding effect of a
potential
Aurora-A modulator prior to actual synthesis and testing.
Methods for screening chemical entities or fragments for their ability to
associate with
Aurora-A are also well known. Often these methods begin by visual inspection
of the active
site on the computer screen. Selected fragments or chemical entities are then
positioned with
the Aurora-A. Docking is accomplished using software such as QUANTA and SYBYL,
following by energy minimization and molecular dynamics with standard
molecular mechanic
forcefields such as CHARMM and AMBER. Examples of computer programs which
assist in
the selection of chemical fragment or chemical entities useful in the present
invention
include, but are not limited to, GRID (Goodford, P. J. J. Med. Chem.1985 28:
849-857),
AUTODOCK (Goodsell, D. S. and Olsen, A. J. Proteins, Structure, Functions, and
Genetics
1990 8: 195-202), and DOCK (Kunts et al. J. Mol. Biol. 1982 161: 269-288).
Upon selection of preferred chemical entities or fragments, their relationship
to each other
and Aurora-A can be visualized and the entities or fragments can be assembled
into a single
potential modulator.
Programs useful in assembling the individual chemical entities include, but
are not limited to
CAVEAT (Bartlett et al. Molecular Recognition in Chemical and Biological
Problems Special
Publication, Royal Chem. Soc. 78,182-196 (1989)) and 3D Database systems
(Martin, Y. C.
J. Med. Chem. 1992 35: 2145-2154).
Alternatively, compounds may be designed de novo using either an empty active
site or
optionally including some portion of a known inhibitor. Methods of this type
of design include,
but are not limited to LUDI (Bohm H-J, J. Comp. Aid. Molec. Design 1992 6: 61-
78) and
LeapFrog (Tripos Associates, St. Louis. MO).
Examples of preferred ligands are found among the above-described indole and
indene
derivatives of formula (I), and optical isomers, physiologically acceptable
salts, derivatives
and prodrugs thereof.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
23
These include especially indole and indene derivatives of formula (I), wherein
R' represents hydrogen, alkylene-NHRs, alkylene-ORg, or alkylene-SRa;
R2 represents hydrogen, alkylene-NHRB, alkylene-ORe, or alkylene-SRB;
R3 represents hydrogen, alkyl, alkylene-R9, alkenylene-R9, alkynylene-R9, or
arylene-R9;
R4 represents hydrogen;
R5 represents hydrogen, alkyl, ORS°, NHR'°, SR'°,
alkylene-R'°, alkenylene-R'°,
alkynylene-R'°, or arylene-R'°;
R6 represents hydrogen, alkyl, OR'°, NHR'°, SR'°,
alkylene-R'°, alkenylene-R'°,
alkynylene-R'°, or arylene-R'°;
R' represents hydrogen;
Rs represents hydrogen, CO-alkyl, (aa)masp(aa)~, (aa)mglu(aa)~, or
(aa)mcys(aa)~;
Rs represents NH-alkyl, N(alkyl)a, N+(alkyl)3, aryl, or heteroaryl;
R'° represents hydrogen, aryl, or substituted aryl;
X represents a nitrogen atom or CH;
as represents an amino acid residue; and
n is zero or an integer of 1 to 10;
m is zero or an integer of 1 to 10,
provided that R' and Ra are not both hydrogen and that R5 and R6 are not both
hydrogen,
and optical isomers, physiologically acceptable salts and prodrugs thereof.
The physiologically acceptable salts in the present case can be acid addition
or base addition
salts.
For acid addition salts, inorganic acids, such as hydrochloric acid, sulphuric
acid, nitric acid
or phosphoric acid, or organic acids, in particular carboxylic acids, e.g.
acetic acid, tartaric
acid, lactic acid, citric acid, malic acid, mandelic acid, ascorbic acid,
malefic acid, fumaric
acid, gluconic acid or sulphonic acids, e.g. methanesulphonic acid,
benzenesulphonic acid
and toluenesulphonic acid, and the like are used.
The base addition salts include salts of the compounds of the formula (I) with
inorganic
bases, such as sodium hydroxide or potassium hydroxide, or with organic bases,
such as
mono-, di- or triethanolamine.
Prodrugs of the compounds of the formula I are, for example, physiologically
easily
hydrolysable esters such as alkyl, pivaloyloxymethyl, acetoxymethyl,
phthalidyl, indenyl and
methoxymethyl esters.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
24
Derivatives of the compounds of the formula I are, for example, compounds
wherein
functional groups such as amino groups and carboxyl groups carry well-known
protecting
groups.
If the compounds according to the invention have asymmetric centres, racemates
and optical
isomers are included as mixtures or in pure form (enantiomers, diastereomers).
The term "alkyl" and the alkyl moieties of alkoxy, alkylthio and
alkoxycarbonyl include
straight-chain or branched alkyl groups, such as CH3, CzHS, n-propyl,
CH(CH3)z, n-butyl,
CH(CH3)-C2H5, isobutyl, C(CH3)3, n-pentyl or n-hexyl, in particular CH3, CzHS
or CH(CH3)z,
preferably having - if not stated otherwise - 1 to 8, in particular 1 to 6 and
particularly
preferred 1 to 4 carbon atoms.
The term "haloalkyl" and the haloalkyl moieties of haloalkoxy include straight-
chain or
branched alkyl groups having 1 to 4 carbon atoms, preferably 1 or 2 carbon
atoms, where
the hydrogen atoms in these groups may be partially or fully replaced by
halogen atoms as
mentioned above, for example C~-Cz-haloalkyl, such as chloromethyl,
bromomethyl,
dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl,
trifluoromethyl,
chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl,
1-bromoethyl,
1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-
chloro-2-fluoroethyl, 2-
chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and
pentafluoroethyl.
Most preferred are perhalogentated C~-Cz-alkyl radicals, especially
trifluormethyl and
pentafluoroethyl.
The term "alkylene" includes straight-chain or branched alkylene groups, such
as methylene
and ethylene, preferably having - if not stated otherwise - 1 to 8, in
particular 1 to 6 and
particularly preferrred 1 to 4 carbon atoms.
The term "alkenylene" includes straight-chain or branched, mono- or
polyunsaturated
alkylene groups, such as ethenylene, preferably having - if not stated
otherwise - 2 to 8, in
particular 2 to 6 and particularly preferably 2 to 4, carbon atoms.
The term "alkynylene" includes straight-chain or branched, mono- or
polyunsaturated
alkylene groups, such as ethynylene, preferably having - if not stated
otherwise - 2 to 8, in
particular 2 to 6 and particularly preferably 2 to 4, carbon atoms.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
The term "cycloalkyl" includes mono- or bicyclic hydrocarbon radicals,
preferably having 5 to
14, in particular 5 to 8, carbon atoms and especially represents cyclopentyl,
cyclohexyl,
cycloheptyl and cyclooctyl.
The term "cycloalkenyl" includes mono- or bicyclic, unsaturated hydrocarbon
radicals,
preferably having 5 to 14, in particular 5 to 8, carbon atoms and especially
represents
cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
"Aryl" is in particular a mono- or bicyclic aromatic radical, preferably
having 5 to 14, in
particular 5 or 6, carbon atoms and especially represents naphthyl, indenyl,
and in particular
phenyl.
"Heteroaryl" is in particular a mono- or bicyclic heteroaromatic radical,
preferably having 5 to
14, in particular 5 or 6, ring atoms and containing 1, 2 or 3 heteroatom(s)
independently
selected from the group consisting of O, N and S. According to a particular
embodiment,
bicyclic radicals contain a 5- or 6-membered heteroaromatic radical which is
benzo-fused.
Heteroaryl includes nitrogen-containing radicals, such as pyrrolyl,
imidazolyl, pyrazolyl,
pyridazinyl, pyrazinyl, indolyl, quinolinyl, especially pyridyl, pyrimidyl and
isoquinolinyl, further
nitrogen-containing radicals such triazolyl and tetrazolyl; radicals which
contain an oxygen
atom or a sulphur atom, such as thienyl, benzothienyl, furanyl and especially
benzofuranyl;
radicals which contain two or more different heteroatoms, such as thiazolyl,
isothiazolyl,
thiadiazolyl, isoxazolyl and oxazolyl. Preferred aromatic heterocyclic
radicals are, pyridyl and
indolyl.
"Saturated and partially- preferably mono - unsaturated heterocyclic radicals"
in particular
include 5- to 7-rnembered heteroaliphatic rings which containing 1, 2 or 3
heteroatom(s)
independently selected from the group consisting of O, N and S. Examples
include 3-
pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-pyrrolidin-2-yl, 2-
pyrrolidin-3-yl, 3-pyrrolidin-2-
yl, 3-pyrrolidin-3-yl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-
piperidinyl, pyridin(1,2-
dihydro)-2-on-1-yl, 2-piperazinyl, morpholin-4-yl and thiomorpholin-4-yl.
Substituted aryl or heteroaryl radicals in particular include those having 1,
2 or 3 substitents
independently selected from the group consisting of halogen, cyano, vitro,
hydroxy, C~-Ca-
alkyl, C~-C4-alkoxy, C~-C4-alkylthio, C~-C4-haloalkyl, C,-C4-haloalkoxy and C~-
C4-
alkoxycarbonyl.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
26
The term "arylene" is preferably naphthylene and in particular phenylene, such
as 1,4-
phenylene.
According to a preferred embodiment, one of residues R' and R2, preferably
residue R2, is
hydrogen while the other, preferably R', has a meaning different from
hydrogen. In this
context, alkylene radicals preferably contain a relatively short main chain
connecting the
indole or indene moiety with the amino, oxy or thio moiety (-NHRB, -ORB or -
SRB,
respectively). Accordingly, the main chain of preferred alkylene radicals
contain 1 to 3
carbon atoms. Said alkyfene radicals may be branched. Linear alkylene radicals
are
preferred. Specific examples of alkylene radicals include methylene, eth-1,1-
ylene, prop-1,1-
ylene and prop-2,2-ylene, with methylene being preferred.
According to a particularly preferred embodiment, one of residues R' and R2,
preferably R~,
is hydrogen and the other, preferably R', represents alkylene-NHRB.
According to a further particularly preferred embodiment, one of residues R'
and R2,
preferably R2, is hydrogen and the other, preferably R', represents alkyfene-
ORB.
RB preferably represents an acyl radical so as to form an amide, ester or
thioester bond
within residue R' and/or R2. It is preferred that residue RB represents an
amino acid selected
from the group consisting of aspartate (asp), glutamate (glu), and cysteine
(cys), i.e., n and
m are zero, or a peptide connected via aspartate, glutamate or cysteine, i.e.,
as represents
an amino acid radical, and at least one of n and m is an integer of 1 or
higher, wherein the
amino acid radicals can be the same or different. The aspartate, glutamate and
cysteine
radicals may be bonded to the alkylene radical via any of their functional
groups. The
aspartate and glutamate radicals are preferably bonded via any of its carboxy
groups, the (3-
carboxy function of aspartate and the y-carboxy function of glutamate being
preferred.
Cystein radicals are preferably bonded via their side chain thio
functionality. Accordingly, the
amino acid radicals as are connected to the alkylene group via the remaining
functional
groups of the aspartate, glutamate or cysteine radicals. According to a
preferred
embodiment, the remaining functional groups are the a-amino group and the a-
carboxy
group, of which one or botl-~ can be bonded to the amino acid radicals aa.
According to this
embodiment, the connecting aspartate, glutamate or cystein radical is itself
part of the
peptide chain which is connected to the alkylene residue via the side chain of
said aspartate,
glutamate or cystein radical. In case both of n and m are zero, the remaining
functional
groups of the aspartate, glutamate or cysteine radicals may be derivatized,
e.g. with groups
that are well-known as corresponding protecting groups from petide synthesis.
These include
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
27
amide-forming acyl groups such as an acetyl group for the a-amino group or
ester-forming
alkyl groups such as an methyl group for the a-carboxy group. Analoguously,
the remaining
functional groups of any amino acid as (in case m and/or n is not zero) can be
derivatized in
a similar manner. A specific example of such a preferred residue R8 is a
radical of the
formula (II)
O
(aa)n HN
~O(aa)m
(II)
O
wherein
as represents an amino acid radical;
n is zero or an integer of 1 to 10; and
m is zero or an integer of 1 to 10.
A specific example of such preferred residues R1 and/or R2 is thus the radical
of formula (III)
O
(aa)n HN
-O(aa)m
(III)
0
HN
/CH2
wherein
as represents an amino acid radical;
n is zero or an integer of 1 to 10; and
m is zero or an integer of 1 to 10.
The amino acid radicals as may be any amino acid. Preferably said amino acid
radicals are
selected to mimick - together with the connecting amino acid - a portion of
TPX2 that binds
to Aurora-A. Said portion of TPX2 is in particular a portion comprising the
amino acid
sequence from residues 7 to 21, preferably 8 to 19 (compare Fig. 3C) or a
fragment thereof.
Accordingly, suitable peptides may have the sequence Tyr-Xaa1-Tyr-Xaa2-Ala-Pro-
Xaa3-
Xaa4-Phe-XaaS-Xaa6-Phe or a portion thereof, wherein Xaa1-6 may be any amino
acid
radical. Xaa1 preferably is a serine radical or a similar amino acid. Xaa2
preferably is an
aspartate radical or a similar amino acid. Xaa3 preferably is a serine radical
or a similar
amino acid. Xaa4 preferably is an aspartate radical or a similar amino acid.
Xaa5 preferably
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
28
is an isoleucine radical or a similar amino acid. Xaa6 preferably is an
asparagine radical or a
similar amino acid. A particularly preferred portion is the sequence Tyr-Xaa1-
Tyr-Xaa2-Ala-
Pro-Xaa3-Xaa4-Phe. By similar amino acid is meant an amino acid that is
considered to
result in a conservative change of the peptide's structure when it replaces
the amino acid to
which it is similar. For instance, aspartate is similar to glutamate. The
peptide preferably has
a lenght of 3 to 15, more preferably of 4 to 10 and advantagously of 5 to 8
amino acid, the
sum of n + m thus being 2 to 14, more preferably of 3 to 9 and advantagously
of 4 to 7,
respectively.
According to a further preferred embodiment, R8 represents hydrogen,
especially in case RZ
is alkylene-OR$ or alkylene-SRa.
According to a further embodiment, R$ represents alkyl, aryl or heteroaryl,
especially in case
RZ is alkylene-NHRa.
According to a further embodiment, one of residues R' and R2, preferably RZ,
is hydrogen
and the other, preferably R', represents hydrogen, C~-C4-alkyl (preferably
methyl) or C~-C4-
haloalkyl (preferably trifluormethyl).
R3 preferably is a radical different from hydrogen and advantageously
represents alkylene-
R9, alkenylene-R9, or alkynylene-R9. In this context, the main chain
connecting the indene or
indole moiety with residue R9 preferably is relatively long. Accordingly, it
is preferred that the
main chain of the alkylene radical, alkenylene radical or alkynylene radical
contains 3 to 8,
e.g. 4, carbon atoms. Said alkylene radical, alkenylene radical and alkynylene
radical may be
branched. Linear radicals are preferred. Specific examples of said radicals
include prop-1,3-
ylene, but-1,4-ylene, pent-1,5-ylene and hex-1,6-ylene, with but-1,4-ylene
being preferred.
R9 preferably represents aryl or heteroaryl. Specific examples of aryl and
heteroaryl radicals
include phenyl, naphthyl, indenyl, pyridyl, and indolyl, with pyridyl, e.g.
pyrid-2-yl, being
preferred. Further specific examples of aryl and heteroaryl radicals include
imidazolyl,
triazolyl and tetrazolyl. R9 may also represent substituted aryl or
heteroaryl.
A specific example of such a preferred residue R3 is a radical of the formula
(IV)
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
29
CH2
H2C
H C CH2 (IV)
2
While residues R4, R5, R6 and R' all may be hydrogen, it is preferred that at
least one of said
residues, especially R6, is different from hydrogen.
R5 and/or R6 preferably represent OR'°, NHR'°, SR'°, or
alkylene-R'°. In this context, the
preferred embodiments regarding the alkylene radical are those as described in
connection
with residues R' and Ra.
R'° preferably represents aryl or substituted aryl. In this context,
aryl is preferably phenyl.
Substituted aryl, in general, contains 1, 2 or 3 substituents which may be the
same or
different, mono-substitution being preferred. The substituents are preferably
selected from
the group consisting of hydroxy, -OP03H~, -CH2P03H2, -CF2P03H2, -COOH, -
CH(COOH)~,
-OP03(R")~, -CH20P03(R")2, -CF2P03(R")2, -COOR", and -CH(COOR")2, wherein R"
is a
radical that is cleavable in vivo, converting the carboxylic acid esters,
phosphate and
phosphonate esters to carboxylates, phosphates or phosphonates, respectively.
Suitable
examples of R" residues are alkyl, CH20C0-alkyl, and C2H4-S-CO-alkyl.
Especially
preferred substituents are selected from the group consisting of -OP03H2, -
CH2PO3H2,
-CF2P03H2, -OP03(R")2, -CH20PO3(R")~, and -CFzPO3(R")~. A preferred example of
a R"
residue is -CH2OC0-alkyl, alkyl being linear or branched and having 1 to 6
carbon atoms,
e.g. methyl. Alternatively, hydroxy is an especially preferred substituent.
Further substituents
include halogen, cyano, nitro, C~-C4-alkyl, C~-C4-alkoxy, C~-C4-alkylthio, C~-
C4-
alkoxycarbonyl.
R'° may also be a moiety that is similar to the above-described . aryl
or substituted aryl
radicals. For instance, R'° may be a cyclic moiety such as a saturated,
partially unsaturated
or aromatic, alicyclic or heterocyclic radical which may be substituted. These
cyclic moieties
include in particular heteroaryl, cycloalkyl, cycloalkylenyl, saturated
heterocyclic and mono-
unsaturated heterocyclic radicals, wherein the heterocyclic radicals
preferably are 5- to 7-
membered and contain 1 or 2 heteroatoms selected from the group consisting of
O, N and S.
The substituents preferably include those for the aryl radicals.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
A specific example of such preferred residues R5 and/or R6 is the radical of
formula (V)
O
O
O
O ~P~ ~ / (V)
O ~-O O
~O
A further specific example of such preferred residues R5 and/or R6 is the
radical of formula
(VI)
\ O\
NI)
HO
According to a specific embodiment, the present invention relates to indole
derivatives of
formula (la)
R1
R6 \
/ ~~ (la)
'N
R3
wherein
R', R3 and R6 are defined as above,
and optical isomers, physiologically acceptable salts and prodrugs thereof.
A preferred indole derivative of the present invention has the formula (15)
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
31
O
(aa)n HN
O(aa)n.,
O
O HN
O~ ,~ O
O_° ~ ~ ,
O p \O / N
~O
a
wherein
aa, n and m are defined as above.
A further preferred indole derivative of the present invention has the formula
(14)
~Me
O
HO jP~\ 14
HO O
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
32
A further preferred indole derivative of the present invention has the formula
(12)
N O
OMe
O
O
\ 12
/ N
HO
/ N
A further preferred indole derivative of the present invention has the formula
(7)
HO
O ~ \
/ N~ 7
HO
The indene and indofe derivatives of formula (I) can be prepared by methods
well-known to
those skilled in the art.
For instance, the above 3-hydroxymethylindole compound (7) is obtainable by
(i) alkylating
the NH group of 5-benzyloxyindole with 1,3-dibromopropane; {ii) removing the
benzy)
protecting group by catalytic hydrogenolysis; (iii) reacting the hydroxy group
with a ben~yl-
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
33
protected p-hydroxyphenylboronic acid; (iv) reacting the 3'-bromine with 2-
methylpyridine; (v)
introducing an aldehyde group in 3-position of the indole nucleus; and (vi)
converting the
aldehyde into a hydroxymethyl group by hydrogenolysis.
Further, the above 3-N-aspartylaminomethyl-5-O-p-hydroxyphenyl-1-N-(4-
pyridylbutyl)-indole
(12) is obtainable by (i) reacting the aldehyde from step (v) above with
hydroxylamine to the
corresponding oxime; (ii) reducing the oxime; (iii) reacting the aminomethyl
group with N-
acetylasparkyl methylester; and (iv) removing the benzyl-protecting group by
catalytic
hydrogenolysis.
Further, the above 3-N-aspartylaminomethyl 5-O-p-hydroxyphenyl-1-N-(4-
pyridylbutyl)-indole
phosphate (14) is obtainable by phosphorylating compound (12) using dibenzyl-
N,N-
diisopropylaminophosphoramidite and subsequent catalytic hydrogenolysis to
remove the
ben~yl-protecting group.
Moreover, further amino acids can be readily attached to the N,O-protected
aspartyl group
using well-known peptide chemistry. To this end, the amino- andlor carboxy-
protecting
groups can be removed in a manner know per se and reacted with appropriate
amino acid
derivatives which usually are themselves protected as required. Both solid
phase and
solution synthesis can be employed.
The present invention is further directed to a method for treating cancer, in
particular breast
and colon carcinomas, comprising administering an effective amount of an
Aurora-A
modulator, such as the indole and indene derivatives as described herein,
preferably an
antagonist or partial antagonist, identified by a computational process of the
invention.
The compounds according to the invention are thus suitable for the treatment
of disorders in
which the interaction of Aurora-A with TPX2 is responsible for the formation
or the
progressive course of these disorders. In particular, the compounds according
to the
invention can be used for the treatment of cancer.
The compounds according to the invention can either be administered as
individual
therapeutic active compounds or as mixtures ~nrith other therapeutic active
compounds: they
can be administered as such, but in general they are administered in the form
of
pharmaceutical compositions, i.e. as mixtures of the active compounds with
pharmaceutically
acceptable excipients, in particular vehicles or diluents and/or additives.
The compounds or
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
34
compositions can be administered enterally, e.g. orally or rectally, or
parenterally, e.g.
subcutaneously, intravenously or intramuscularly.
The nature of the pharmaceutical composition and of the pharmaceutical carrier
or diluent
depends on the desired manner of administration. Oral compositions can be
present, for
example, as tablets or capsules and can contain customary excipients, such as
binding
agents (e.g. syrup, acacia, gelatin, sorbitol, tragacanth or
polyvinylpyrrolidone), fillers (e.g.
lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine),
lubricants (e.g.
magnesium stearate, talc, polyethylene glycol or silica), disintegrating
agents (e.g. starch) or
wetting agents (e.g. sodium laurylsulphate). Oral liquid preparations can be
present in the
form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs or
sprays etc. or
can be present as dry powders for reconstitution with water or another
suitable carrier. Liquid
preparations of this type can contain customary additives, for example
suspending agents,
flavourings, diluents or emulsifiers. For parenteral administration, solutions
or suspensions
with customary pharmaceutical carriers can be employed.
The following examples are to illustrate the invention, but should not be
interpreted as a
limitation thereon.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
Examples
Experimental Procedures
Protein and Antibody Preparation
Aurora~N was cloned in pET M11 (residues 122-403, wild-type and D274N) were
expressed
in CodonPlus RIL E.coli (Stratagene) and purified with TALON resin (Clontech)
using
manufacturer's instructions. Aurora~N was treated with TEV protease to remove
the His tag,
passed through a TALON column to remove TEV and then purified to homogeneity
by size
exclusion chromatography. Human and Xenopus GST TPX2 fragments were expressed
in
BL21 (DE3) E.coli. TPX2 proteins were purified using glutathione sepharose
(Pharmacia). To
form the AuroraON-TPX2 complex, cell lysate from E.coli expressing GST TPX2
was passed
through a glutathione sepharose column, washed, and then purified Aurora~N was
passed
through the same column. Column resin was incubated with TEV protease to elute
the
complex, which was further purified by size exclusion chromatography.
The polyclonal antibody against full-length TPX2 was produced in rabbits with
bacterially
expressed GST TPX2 (Wittmann et al., 2000) and affinity purified. The 1 C1
monoclonal anti-
Xenopus Aurora-A is described in: Giet R, Uzbekov R, Cubizolles F, Le Guellec
K, Prigent
C., J Biol Chem. (1999) 274, 15005-13. The polyclonal anti-human Aurora-A was
obtained by
injecting rabbits with bacterially expressed full-length human Aurora-A.
HeLa cell extract and Xenopus egg extract preparation
HeLa cells (CCL2; ATCC, Mantissas, VA) were grown in 10% fetal calf serum
(FCS) and
2 mM L-glutamine in modified Eagle's medium at 37°C and 5% C02. Cells
were arrested in S
phase using a double thymidine (2 mM) block as described (Stein, 1994) and
released from
S phase by washing away the thymidine. After 10 h, cells were trypsinized,
incubated for 10
min in ice-cold lysis buffer (25 mM Tris pH 7.6, 200 mM NaCI, 1 % Triton,
protease inhibitors),
and centrifuged for 10 min at 15,000 g. Xenopus cytostatic factor arrested
extracts (CSF
extracts) were prepared as described (Murray, 1991 ).
In vitro kinase assay
Full-length TPX2, TPX2(1-43) or TPX2(15-43) at 4 p,M were incubated with full
length
Aurora-A or Aurora~N in kinase buffer (20 mM Hepes pH 7.5, 200 mM KCI, 5 mM
MgCl2, 0.5
mM EGTA, 1 mM DTT, 0.05 % Triton X-100, 50 pM ATP) containing y32P-ATP
(Amersham)
in the presence or absence of histone H3 (0.2 mg/ml, Roche), for 15 min at
25°C. For
cleavage, GST TPX2(1-43) was incubated with TEV 16-18h at 4° C (Figure
2C) or by adding
TEV after the kinase reaction and incubating 10 min at 30° C (Figure 1
D). In Figure 2D,
AuroraON (8~,M) was incubated in kinase buffer containing histone H3 and y3~P-
ATP for 15
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
36
min at 25° C. After separation by SDS-PAGE, phosphorylated histone H3
and TPX2 proteins
were detected by autoradiography.
Phosphatase assay
Active human Aurora-A (2 ~M) was incubated with TPX2, TPX2(1-43) or TPX2(15-
43) (3 p.M)
for 10 min at 4°C. Samples were diluted in phosphatase buffer (50 mM
Tris-HCI pH 7, 0.1
mM EDTA, 1 mM MnCl2, 5 mM caffeine, 5 mM DTT, 0.025% Tween 20) and incubated
in the
absence or presence of PP1 (a isoform, NEB) for 0.5h at 30°C.
Afterwards proteins were
separated by SDS-PAGE and analyzed by Western blotting with anti-Aurora-A or
anti-
phospho-Aurora-A (Cell Signalling, 1:10000 dilution).
Immunoprecipitation
For coating beads with anti-GST, 6 p.g of antibody were incubated with 20 ~,I
of protein A-
conjugated Dynabeads 280 (Dynal) in a total volume of 100 pl PBS-T (PBS, 0.1 %
Triton X-
100), for at least 1 h at 4°C. The beads were washed twice with PBS-T
and twice with HeLa
cells lysis buffer or CSF-XB (10 mM Hepes pH 7.7, 50 mM sucrose, 100 mM KCI, 2
mM
MgClz, 0.1 mM CaCl2 and 5 mM EGTA). 50 ~l extract was incubated with GST, GST
TPX2 1-
43, GST TPX2 15-43, GST TPX2 Xenopus or GST TPX2( 1-39) Xenopus proteins
(final
concentrations: 250 nM Xenopus; 1 p,M HeLa) in the absence or presence of
RanQ69L-GTP
(16 p.m) for 15 minutes at 20 °C and then added to the beads. After 1 h
incubation on ice, the
beads were washed twice with lysis buffer or CSF-XB, washed twice with PBS-T
and boiled
in SDS-PAGE sample buffer. The samples were then subjected to gel
electrophoresis and
analyzed by Western blotting with anti-GST, anti-Xenopus TPX2, anti-Xenopus
Aurora-A or
anti-human Aurora-A.
In vitro putt-down assays
GST or GST TPX2(1-43) (240 fig) was bound to 100 ~I glutathione sepharose
(Pharmacia) in
1 ml binding buffer (PBS, 0.05% Tween-20, 2 mM DTT) for 0.5 h. Beads were
washed three
times, divided into four equal quantities in 1 ml binding buffer and 35 ~,g
full-length human
Aurora-A, Aurora~N or Aurora~N(D274N) was added. After binding for 0.5 h at
4°C, the resin
was washed four times, then incubated overnight in 50 ~,I binding buffer plus
2 ~g TEV
protease. 10 p,l supernatant from each was analysed by SDS-PAGE. TEV cleavage
was
necessary because AuroraON and GST TPX 1-43 co-migrate by SDS-PAGE.
Crystallographic methods
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
37
Needle-like crystals of Aurora~N in complex with TPX2 1-43, approximately 10
p,m in
thickness, were grown at 18°C by vapour diffusion using 18% (w/v)
PEG8000, 100 mM MES
pH 6.5, 200 mM MgS04 as well buffer and hanging drops comprising a 1:1 mix of
20 mg/ml
complex pre-mixed with 2 mM ATPyS and 0.2 mM MgS04, and 20% PEG8000, 100 mM
MES pH 6.5, 200 mM MgS04. For cryo-protection, the drop buffer was
supplemented with
17.5% (v/v) glycerol. Hexagonal prism crystals of the wild-type Aurora~N
kinase alone,
approximately 50pm in all dimensions, were grown by vapour diffusion using 20%
PEG300,
5% PEG8000, 100 mM Tris 8.5, 10% glycerol as well buffer and sitting drops
comprising a
1:1 mix of well buffer and 9 mg/ml protein pre-incubated with 2 mM ATPyS and 2
mM
MgS04. Diffraction data were collected at 1 OOK and processed using the CCP4
suite of
programs (CCP4, 1994). Structures were solved by molecular replacement using
CNS
(Brunger et al., 1998) and the coordinates of the cAMP-dependent protein
kinase catalytic
subunit as an initial model (Mashhoon et al., 2001 ). CNS was used for
refinement and O
(Jones et al., 1991) for model building. The statistics for data collection
and refinement are
shown in Table 1. Structure figures were prepared using PyMOL (DeLano, 2002).
Coordinates and structure factors have been deposited in the Protein Data Bank
with
accession codes 1017 and 1015 for phosphoryated Aurora~N alone and in complex
with
TPX2(1-43), respectively.
Mapping of a minimal domain of TPX2 sufficient for binding and activating
Aurora-A
A minimal domain of TPX2 sufficient to interact with Aurora-A was mapped. The
Aurora-A
binding domain of TPX2 resides within its N-terminal 150 residues. Inspection
of a sequence
alignment of TPX2 shows that only a third of this region is conserved across
species
(residues 1-43 in human TPX2, 1-39 in Xenopus TPX2). This fragment is able to
co-
immunoprecipitate Aurora-A from Xenopus egg extracts to the same extent as the
full-length
protein (Figure 1A, lanes 6 and 4 respectively). In the egg extracts,
efficient binding of TPX2
to Aurora-A requires Ran locked into its GTP-bound form (RanQ69L), which
releases TPX2
from a complex with importin al(3. Xenopus TPX2(1-39) binds Aurora-A in a
RanGTP-
independent manner (Figure 1A, lanes 5 and 6), consistent with it lacking the
portion of TPX2
regulated by Ran. The corresponding fragment of human TPX2 (residues 1-43) is
able to
interact with Aurora-A using pull-down experiments in HeLa extract, while a
shorter construct
encompassing residues 15-43 is unable to do so (Figure 1 B, lanes 2 and 3
respectively).
The minimal Aurora-A binding domain of human TPX2(1-43) is sufficient to
stimulate the
activity of the kinase in vitro (Figure 1 C). Phosphorylation of histone H3,
an Aurora-A
substrate, is markedly increased by the addition of TPX2(1-43) (Figure 1C
compare lane 1
with lane 3), but not by the shorter TPX2(15-43) (lane 4). Full-length TPX2
also increases the
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
38
activity of the kinase, but appears less effective than the fragment. Full-
length TPX2 may
require additional factors such as microtubules for full activation. While
microtubules can
stimulate TPX2 activation of Aurora-A, no enhancement is detected for TPX2 1-
43, which
does not bind microtubules. Full-length TPX2 is itself a substrate for Aurora-
A. The
phosphorylation observed for GST-fused TPX2(1-43) (Figure 1 C, lane 3) is
however likely a
non-specific artifact of the in vitro reaction because upon cleavage of the
fusion protein
phosphorylation signal is also detected on GST (lane 2). Furthermore, mass
spectroscopy
does not reveal Aurora-A phosphorylation sites in full-length TPX2.
The presence of TPX2(1-43) protects Aurora-A from deactivating
dephosphorylation (Figure
1 E). In the absence of TPX2, Aurora-A is completely dephosphorylated by
phosphatase PP1
(lanes 1 and 2). 1n the presence of full-length TPX2, PP1 treatment
dephosphorylates most
sites of Aurora-A (lanes 3 and 4, upper panel) but prevents dephosphorylation
of Thr288AU~
(lane 4, lower panel, arrow). An even stronger protection effect is observed
upon addition of
TPX2(1-43) (lane 6). In the presence of TPX2 15-43, Aurora-A is fully
dephosphorylated as
in the absence of TPX2 altogether (lanes 8 and 2), consistent with the shorter
fragment being
unable to bind Aurora-A (Figure 1 B). Thus, residues 1-43 of human TPX2 are
necessary and
sufficient for Aurora-A binding, activation and protection from
dephosphorylation.
Overall structure of TPX2-bound Aurora-A
For crystallisation purposes, a minimal functional complex of Aurora-A and
TPX2 was
focused on. The N-terminus of Aurora-A is overall poorly conserved across
species and is
not required to bind TPX2. A fragment of Aurora-A tacking the N-terminus
(residues 122-403,
AuroraON) interacts with the active fragment of TPX2 (1-43) as efficiently as
the full-length
kinase (Figure 2A lanes 5 and 4). Both fragments are highly conserved (Figure
2D, 2E) and
indeed ?Cenopus TPX2(1-39) can bind human Aurora~N. AuroraON is phosphorylated
when
expressed in E. coli, as detected by a phospho-specific antibody (Figure 2B,
lane 1 ). This
appears to be due to Aurora-A autophosphorylation rather than to the activity
of a bacterial
kinase, since no phosphorylation can be detected upon expressing a mutant
where an
important catalytic residue, Asp274AUR, has been mutated to Asn (Figure 2B,
lane 2). The
unphosphorylated mutant is catalyticaliy inactive but retains TPX2-binding
activity (Figure 2A,
lane 6). AuroraON is activated by TPX2(1-43) (Figure 2C, lanes 2,3).
The complex between human phosphorylated Aurora~N and TPX2(1-43) is active in
histone
H3 phosphorylation (Figure 2C, lane 7). The complex was crystallized in the
presence of
Mg~+ ions and the ATP analogue ATPyS. The structure was determined by
molecular
replacement and refined it using 2.5 A resolution data to a Rfree of 25.2%
(see Table 1 ). The
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
39
polypeptide model includes the catalytic core of the kinase (residues 123-
387AUR) and two
segments of TPX2 (residues 7-21 TPx and 30-43TPx). No ordered electron density
is present
for the eight intervening residues of TPX2 (22-29TPx), which have therefore
not been
modelled.
The kinase catalytic core has an overall bilobate structure (Figure 3A,B).
Briefly, the N-
terminal lobe (residues 123-210) consists of a (i-sheet and two a-helices,
including the
prominent helix a,C whereas the C-terminal and larger lobe (residues 217-387)
is mostly a-
helical. The active site is situated at the interface between the lobes and
includes the ATP-
binding site, the catalytic base (Asp256AUR) and the kinase activation segment
(residues 274-
299AUR). In contrast to the structure of unphosphorylated Aurora-A, the
activation segment is
well ordered in the electron density and includes two phosphorylated threonine
residues
(Thr287AURand Thr288AUR). Although the crystals were formed in the presence of
ATP-yS,
the electron density for the nucleotide reveals only the adenosine with two
ordered
phosphates and has been modelled as an ADP.
Specific recognition of TPX2 at two sites on Aurora-A
TPX2 binds Aurora-A with two separate stretches recognized at two distinct
sites on the
kinase. The upstream stretch (residues 7-21TPx) binds at the N-terminal lobe
of Aurora-A
(Figure 3A,B). The downstream stretch (residues 30-43TPx) binds in a a-helical
conformation
between the N- and C-terminal lobes (Figure 3A, B). The two Aurora-A-binding
motifs of
TPX2 appear to be connected by a flexible linker (disordered in the structure)
that is variable
in length and sequence across species (Figure 2D). Additionally, the two
stretches are
connected by an intramolecular hydrogen bond between Asp11TPx and Trp34TPx.
The upstream stretch of TPX2 has a mostly extended conformation, with a kink
in the middle
induced at a proline residue (Pro13TPx) (for details see Figure 3C). The
conserved segment
$YSYDAPS'4 (Figure 2D) is engaged in extensive main-chain and side-chain
interactions
with Aurora-A. In particular, Tyr8TPx, Tyr10TPx and Ala12TPx tightly nestle
into a hydrophobic
groove between the ~-sheet, helix aB and helix a,C. An adjacent hydrophobic
groove
accommodates the side chains of TPX2 residues from Phe16TPx to Phe1gTPx. The N-
terminal
residues of the Aurora-A catalytic core make key contributions to this
interface, in particular
with Arg126AUR forming a cation-~ interaction with Phe16TPx.
The downstream helical stretch of TPX2 interacts with both helix aC and the
activation
segment of Aurora-A, bridging them (see Figure 3D for details). Most
prominently, two
conserved aromatic residues (Trp34TPx and Phe35TPx) interact with His187AUR
and
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
His280AUR and Ala39TP" additionally contacts the activation segment at
Pro282AUR. While the
side of the TPX2 helix in contact with the kinase is lined by hydrophobic and
conserved
residues, the opposite side exposed to solvent comprises hydrophilic and
variable residues.
Residues 40-43TPx at the end of the helix assume an extended conformation and
are
involved in contacts with a symmetry-related Aurora-A molecule within the
crystal lattice.
TPX2 is phosphorylated in mitotic extracts and may well be regulated by
phosphorylation.
Even if TPX2 was phosphorylated in the first 43 residues, examination of the
crystal structure
suggests that the interaction of TPX2 with Aurora-A is unlikely to be
regulated this way
because all the conserved serine residues point towards solvent.
Phosphorylated Aurora-A is in an active conformation when bound to TPX2
Comparison with other kinase structures reveals that phosphorylated TPX2-bound
Aurora-A
closely matches the conformation of kinases in the active conformation. Using
the program
DALI (Holm and Sander, 1993), it was found particularly similar to CAMP-
dependent protein
kinase (PDB code 1YDS, 1.3 A r.m.s.d., 257 structurally equivalent residues).
Structural
comparison shows that all the conserved residues at the active site are
correctly oriented for
catalysis (Figure 4A). These include the positively-charged residue aligning
the phosphates
for catalysis (Lys162AUR, equivalent to Lys72~PK), the negatively-charged
residue
coordinating the magnesium ion bound to the nucleotide (Asp274AUR, equivalent
to
Asp184~'PK), and the catalytic base (Asp256AUR, equivalent to Asp166~PK) whose
role is to
transfer the y-phosphate of ATP to the hydroxyl group of a substrate serine or
threonine
residue.
The phosphorylated activation segment of TPX2-bound Aurora-A is in a
conformation typical
of active Ser/Thr kinases. It is virtually superposable to that of active cAPK
(Figure 4A), with
an r.m.s.d. of 0.8 A between the Caatoms of residues 274-299AUR and 184-
208~PK. In cAPK,
the phosphorylated Thr197°°'PK interacts with
Arg165°°°'PK and with a basic surface patch
(His87~'PKand Lys189~P~), influencing the preceding catalytic residue
(Asp166~P~). In
Aurora-A, the phosphoryl moiety of Thr288AUR is at the same structural
position and interacts
with the corresponding Arg255AUR and with a similar, though not identical,
basic patch
(Arg180AUR and Arg286AUR), linking the catalytic residue (Asp256AUR) to helix
aC and to the
activation segment. Mutation of Thr288AUR to Asp generates a protein more
active than
unphosphorylated wild-type Aurora-A, but much less active than the
phosphorylated wild-
type kinase. This mutation is thus a poor mimic of phosphorylation at
Thr288AUR, and
although a Glu may potentially produce a stronger effect by more closely
approximating the
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
41
substrate-binding site rather than providing a substrate-binding platform. The
phosphorylated
Thr288AUR has no direct connection with TPX2, the phosphate moiety being 14 A
from the
nearest TPX2 atom. Nonetheless, TPX2 induces a 10 A movement of the phosphoryl
moiety
required to achieve the active conformation (Figure 4B).
The helical stretch of TPX2 contacts the activation segment at His280AUR and
Pro282AUR,
which appear to be the pivot points of the conformational change (Figures 4B,
4C). In
essence, a rotation about His280AUR swings Pro282AUR and Ser283AUR towards the
TPX2
helix, pulling downstream residues of the activation segment to pack more
closely with the
kinase core (Figure 4B). In this lever-arm-like mechanism, a small change at
the pivot points
(His280AUR, Pro282AUR) produces a large movement in the arm (P-Thr288AUR
Figure 4C).
While in the unbound form the activation segment is rather mobile and has
probably
sufficient conformational freedom to adopt an active conformation in the
presence of
substrate (basal kinase activity, Figure 1 C, lane 1 ), in the TPX2-bound
form, the active
conformation is ready for substrate binding and catalysis (increased kinase
activity, Figure
1C, lanes 2 and 3). The C-terminal residues (40-43TPX) protruding from a
neighbouring TPX2
molecule in the crystals bind to the activation segment, albeit in the
opposite main chain
direction to a real substrate. Substrate binding alone does not fully activate
Aurora-A in
solution (Figure 1 C), and it is therefore very unlikely that this substrate-
like contact is
responsible for the active conformation in the crystal structure. Substrate
binding, however,
might assist in inducing an active conformation, especially in the absence of
TPX2.
In addition to enhancing the activity of Aurora-A, TPX2 also protects the
kinase from
dephosphorylation by phosphatases. The site for PP1 binding on Aurora-A is
mapped to the
C-terminus, a region that is distant from the TPX2 binding site and that is
structurally
unaffected upon binding of the regulator. Thus TPX2 is unlikely to protect
Aurora-A from
dephosphorylation by preventing phosphatase binding. Indeed, even in the
presence of
TPX2, the phosphatase is capable of removing the phosphates from most side
chains with
the exception of Thr288AUR (Figure 1 E). TPX2 prevents Thr288AUR
dephosphorylation by
moving the phosphate moiety from a solvent-exposed position to a buried
position, which is
inaccessible to an incoming phosphatase. The other phosphorylated threonine in
the kinase
catalytic core, Thr287AUR, is conspicuously exposed to solvent and may serve
as a decoy to
further mask Thr288AUR (Figure 3B).
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
42
Table 1. Summary of crystallographic analysis
Phospho- Phospho-
Aurora-A Aurora-A
+ TPX2
Crystals
Spacegroup P2~2~2~ P6~22
Lattice constants 59.63 81.18
a (A)
b (A) 81.72 81.18
c (A) 83.05 169.62
Data collection
X-ray source SLS X06SA ESRF ID14EH1
Resolution range 40-2.5 70-2.75
(A)
(Highest resolution(2.64-2.5) (2.9-2.75)
shell)
Unique reflections 14609 9235
Completeness(%) 100 (100) 100 (100)
Multiplicity 5.6 (5.7) 10.1 (10.6)
Rmerge (%) 9.9 (24.8) 11.9 (34.6)
I/a(I) 5.1 (1.1 3.8 (2.1
) )
Refinement
Resolution range 40-2.5 20-2.75
(A)
Number of residues294 263
Number of waters 144 9
Rfactor (%) 19.4 25.7
Rfreea (%) 25.2 29.6
Ramachandran plot
Most favoured (%) 91.5 82.4
Allowed (%) 8.1 16.3
Generously allowed (%) 0.0 0.9
Forbidden (%) 0.4b 0.4b
a Free Rfactor was computed using 5% of the data assigned randomly (Brunger,
1992).
b Ser226AUR resides in a loop and the conformation is supported by excellent
electron
density.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
43
Synthesis of indole compounds of formula (I)
Synthesis of 3-hydroxymethyl-5-O-p-hydroxyphenyl-1-N-(4-pyridylbutyl)-indole
(7)
As outlined below in Scheme 1, the synthesis started from 5-benzyloxyindole
~1). Alkylation
of the amino group of (1) with 1,3-dibromopropane was achieved in the presence
of NaH in
dimethylformamide (DMF) giving the 3'-bromopropyl compound (2). Catalytic
hydrogenolysis
in the presence of palladium on charcoal (10%) removed the benzyl-protecting
group
quantitatively. The resulting compound (3) was alkylated at the hydroxy group
with a benzyl-
protected p-hydroxyphenylboronic acid in the presence of organic base,
copper(II)acetate,
and molecular sieves (4A) in dichloromethane (DCM) at 40°C. The
resulting 5-O-
phenylindole compound (4) was further alkylated to compound (5) by replacing
the bromine
with 2-methylpyridine in the presence of lithiumdiethylamide (LDA) in
tetrahydrofurane (THF)
at -78°C. In order to attach more functional groups to the indole ring,
(5) was reacted with
DMF and phosphorylchloride (POCI3) to give aldehyde (6). Palladium-catalyzed
hydrogenolysis in ethylacetate gave target compound (7) in quantitative yield.
All compounds
were characterized by'H- and '3C-NMR as well as mass spectroscopy.
Scheme 1:
B(OH)z
\ Br~Br Hz, PdIC, HO / ~
Bn0 / Bn0 \ ~ ~ Et~ ~ B
0
I N n
NaH, DMF --
Cu(OAc)z, MS4A
Bn0 N
TEA,/Py, DCM,
40C
Br Br Br
~ LDA,
THF,
-78C
Hp, Pd/C,
EtDAc
Bn POCI3, DMF
Synthesis of 3-hydroxymethyl indole compound 7.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
44
Synthesis of 3-N-aspartylaminomethyl-5-O-p-hydroxyphenyl-1-N-(4-pyridylbutyl)-
indole (12)
As outlined below in Scheme 2, the above compound (5) was subjected to
Vilsmeyer
formylation in DMF/POCI3, which gave aldehyde (8). The latter was reacted with
hydroxylamine in DCM in the presence of molecular sieves to give oxime (9).
Reduction of
the oxime was achieved by zinc in acetic acid. The resulting aminomethyl
compound (10)
was too labile to be isolated. Instead, the crude mixture was directly reacted
with N-
acetylaspartyl methylester under standard peptide synthesis conditions
(diisopropylcarbodiimide, diisopropylethylamine, DCM). The
aspartylaminomethylindole
compound (11 ) was subjected to hydrogenolysis conditions (palladium on
charcoal 10%,
ethanol) with ammonium formiate as hydrogen donor. The resulting hydroxyphenyl
compound (12) was isolated in good yield. All compounds were characterized
by'H- and
'3C-NMR as well as mass spectroscopy. Selected data for (12): MS (ESI pos.
mode): 581.2
CM+Na+l.
Scheme 2:
H~NOH HCI,
POCIy, DMF MS4A, DCM
NH4C00, Pd/C,EtOH
Me00C
~NHAc
(\COO H
DIC,DIPEA, DCM
Synthesis of 3-N-aspartylaminomethyl 5-O-p-hydroxyphenyl 1-N-(4-pyridylbutyl)
indole compound 12.
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
Synthesis of 3-N-aspartylaminomethyl-5-O-p-hydroxyphenyl-1-N-(4-pyridylbutyl)-
indole
phosphate (14)
As outlined below in Scheme 3, the above compound (12) was phosphorylated by
standard
phosphorus(III) chemistry using dibenzyl-N,N-diisopropylaminophosphoramidite
in the
presence of dicyanotriazole in acetonitrile under stirring for 12 hours. The
mixture was
subsequently cooled to -30°C and t-butylperoxyhydroxide was added. The
resulting
phosphoric acid triester (13) was purified by preparative reversed phase
chromatography.
Palladium-catalyzed hydrogenolysis quantitatively gave the unprotected 3-N-
aspartylaminomethyl-5-O-p-hydroxyphenyl-1-N-(4-pyridylbutyl)-indole phosphate
(14). All
compounds were characterized by'H-, 3'P-, and '3C-NMR as well as mass
spectroscopy.
Selected data for (14): 3'P-NMR: b = -2.17 ppm. MS (ESI pos. mode): 639.0
[M+H+].
Scheme 3:
1. (iPr)ZNP(OBn)2, tetrazole,
MeCN
2. tBu00H, -30°C
NHyC00, Pd/C,EtOH
Phosphoryiation of 3-N-aspartylaminomethyl 5-O-p-hydroxyphenyl 1-N-(4-
pyridylbutyl) indole compound to
the corresponding phosphate ester 14.
Determination of the inhibition of Aurora A by the compounds of the present
invention
The ability of compounds (7) and (12) to inhibit Aurora A was tested in a
luminescence ATP
detection assay system for kinase applications. Briefly, the compound of the
present
invention was added to a solution of Aurora A in HEPES buffer (150 nM Aurora
+I- TPX2, 25
mM HEPES pH 7.4, 5 mM MgCl2, 0.01 % Tween 20; 0.1 % BSA; 100 pM Kemptide
[Promega
Corporation, Madison, WI]); final assay concentrations). The addition of an
ATP solution (20
pM final concentration) initiated the reaction. The reaction was carried out
for 20 min at room
temperature and terminated by the addition of equal volumes of EasyLite
Solution (Perkin
Elmer Corporation, Boston, MA) followed by monitoring the luminescence in a
Wallac
Envision plate reader (Perkin Elmer Corporation, Boston, MA). The EasyLite-
Kinase~ is an
CA 02540810 2006-03-29
WO 2005/040368 PCT/EP2004/011381
46
ATP monitoring system based on firely (Photinus pyralis) luciferase for the
evaluation of
kinase activity. The system relies on the consumption of ATP during a kinase
reaction and is
commercially available.
As can be taken from the following table, both compounds, (7) and (12),
inhibited Aurora
significantly (but not protein kinase A, PKA).
Compound Aurora Aurora + TPX2 PifA
IC50 (pM) IC50 (pM) IC50 (pM)
(7) 79 +/- 4 > 500 > 500
(12) 37 +/- 4 37 +l- 16 > 500
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPRI~:ND PLUS D'UN TOME.
CECI EST L,E TOME 1 DE 2
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional valumes please contact the Canadian Patent Office.
